Sales Growth: 18% in the first three months of 2025. Operating Profit Growth: 20% in the first three months of 2025. US Operations Sales Growth: 17% in the first three months of 2025. International Operations Sales Growth: 19% in the first three months of 2025. GLP-1 Diabetes Sales Growth: 11%, with US operations growing 10% and International Operations growing 13%. Obesity Care Sales Growth: 65%, with US operations growing 40% and International Operations growing 137%. Rare Disease Sales Growth: 3%, with International Operations growing 5% and US operations growing 1%. Gross Margin: Decreased to 83.5% from 84.8% in the first three months of 2024. Net Profit Increase: 14% in the first three months of 2025. Diluted Earnings Per Share: Increased by 15% to DKK6.53. Free Cash Flow: DKK9.5 billion compared to DKK5 billion in the first three months of 2024. Capital Expenditure: DKK13.4 billion compared to DKK8.4 billion in 2024. Return to Shareholders: DKK36.7 billion, mainly as dividends in the first three months of 2025.

Warning! GuruFocus has detected 1 Warning Sign with NVO.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Novo Nordisk AS (NYSE:NVO) reported an 18% sales growth and 20% operating profit growth in the first quarter of 2025. The company is serving nearly 46 million patients with diabetes and obesity treatments, an increase of almost 4 million from the previous year. Novo Nordisk AS (NYSE:NVO) completed the pivotal trial REDEFINE 2 for its next-generation obesity treatment, CagriSema, and remains on track for submission in early 2026. The US FDA accepted the application for Wegovy 2.4 mg for treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review. Novo Nordisk AS (NYSE:NVO) has expanded its presence in the US with over 10,000 full-time employees and significant investments in manufacturing sites.

Negative Points

Total carbon emissions increased by 37% due to the acquisition of new production sites and capital expenditure activities. The company reduced its full-year outlook due to lower-than-planned branded GLP-1 penetration, impacted by the rapid expansion of compounding in the US. Novo Nordisk AS (NYSE:NVO) faces challenges with unlawful compounding of semaglutide in the US, affecting the uptake of Wegovy prescriptions. The gross margin decreased to 83.5% from 84.8% in the first quarter of 2024, mainly due to amortizations and depreciations related to Catalent. Net financial items showed a net loss of DKK1.8 billion, primarily reflecting losses on hedge currencies and financing costs related to the Catalent transaction.

Story Continues

Q & A Highlights

Q: How does Novo Nordisk plan to address the issue of compounding in the US, especially with partnerships like HIMSS? A: David Moore, Executive Vice President, US Operations, stated that Novo Nordisk does not support unlawful compounding and is against illegal importation and continuation of compounding in the US. The company has collaborated with telehealth providers to ensure patients have access to legitimate Wegovy through Novocare Pharmacy. They expect the FDA to enforce the law against unlawful compounding by May 22.

Q: What are the expectations for Ozempic growth in International Operations once supply constraints are removed? A: Maziar Doustdar, Executive Vice President, International Operations, explained that Ozempic has been launched in 80 markets and is expected to see accelerated growth as supply constraints are lifted. The company has a 64% volume market share on injectable GLP-1s and plans to continue promoting Ozempic aggressively.

Q: Can you provide more details on the impact of compounding on Wegovy market share and the guidance for the second half of the year? A: Karsten Munk Knudsen, Chief Financial Officer, noted that the guidance assumes a significant number of patients on compounded products will switch to branded products in the second half of the year. The company expects to capture patients transitioning from compounded semaglutide to branded Wegovy, supported by cash offerings and telehealth collaborations.

Q: How does Novo Nordisk view the competitive landscape with Mounjaro and the potential for Ozempic growth? A: David Moore highlighted that the GLP-1 class continues to grow, and Novo Nordisk is focused on leveraging the broad label of Ozempic. The company has launched a new campaign, "Ozempic Era," to emphasize the benefits of the product and aims to maintain patient retention and increase dosage adherence.

Q: What is the outlook for oral semaglutide 25-milligram, and how does Novo Nordisk plan to compete in the oral GLP-1 market? A: Lars Fruergaard Joergensen, CEO, stated that Novo Nordisk is well-positioned to launch oral semaglutide 25-milligram, assuming positive regulatory outcomes. The company believes the oral segment will be smaller than injectables but is confident in competing effectively with a known molecule that offers convenience and efficacy similar to Wegovy.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments